News

Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade)
Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...
Lilly to offer highest doses of weight-loss drug Zepbound on website
Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...
KYMA1d
Eli Lilly announces price cut for Zepbound
Eli Lilly is reducing the price of the highest doses of its popular drug Zepbound for folks who aren't using insurance.
Fierce Pharma22h
Eli Lilly adds high-dose Zepbound options to lineup of cheaper vials available on self-pay website
Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...
Eli Lilly Launches Flat Pricing For Zepbound, Capping Monthly Cost At $499
Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...
PharmExec19h
Lilly Launches Full Zepbound Dose Access for Obesity Through LillyDirect Self-Pay Program
Starting July 7, 2025, the two highest doses of Zepbound will be available for a flat price of $499 per month, with shipments ...
Reuters on MSN20h
Lilly will offer higher doses of Zepbound on its website
Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...
Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock
Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...
STAT2h
Eli Lilly to buy gene-editing biotech Verve for up to $1.3 billion
Eli Lilly said Tuesday that it will acquire Verve Therapeutics, a biotech developing gene-editing therapies for cardiovascular disease.
Down 12%, Should You Buy the Dip on Eli Lilly?
Eli Lilly ( LLY 0.36%) has been a great growth pick for investors over the past few years. The pharma company, thanks to its ...